Aydin Huseynov, M.D., CFA
Managing Director, Biotechnology Equity Research
Dr. Huseynov is an Equity Research Analyst covering Biotechnology companies. Prior to joining Ladenburg, he was Managing Director, Senior Equity Research Analyst at Benchmark Company, LLC, covering large-, mid-, and small-cap biotech companies. Before Benchmark, Dr. Huseynov worked on the Biotechnology Equity Research team at Oppenheimer & Co. Inc. Prior to Oppenheimer, he worked as a strategy consultant at Syneos Health Consulting where he advised biopharma companies in R&D, clinical, commercial, valuation, and market access projects, and as a corporate strategist at Teva Pharmaceuticals. Earlier in his career, he was a practicing physician and entrepreneur. Dr. Huseynov holds an MBA degree from The Fuqua School of Business, Duke University, an M.D. from Azerbaijan Medical University, and an MS in International Economic Relations from Khazar University. He is a CFA Charterholder.